News

Filter

Current filters:

GW PharmaceuticalsUK

Highlights from the Jefferies 2014 Global Healthcare Conference

Highlights from the Jefferies 2014 Global Healthcare Conference

21-11-2014

Pharma, biotech and health care companies convened in London this week to update investors at the Jefferies…

ALK AbelloClinigen GroupCubistFinancialGW PharmaceuticalsPeter GeorgePharmaceuticalUK

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

GW Pharma shows drop in revenue but expects ‘steady progress’

GW Pharma shows drop in revenue but expects ‘steady progress’

07-05-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

FinancialGW PharmaceuticalsNeurologicalPharmaceuticalSativexUK

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

07-05-2014

UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created…

BoardroomGW PharmaceuticalsPharmaceuticalUKUSA

US FDA grants Sativex fast track status for cancer pain

US FDA grants Sativex fast track status for cancer pain

28-04-2014

UK-based GW Pharmaceuticals, which focuses on its proprietary cannabinoid product platform, today announced…

Advanced cancerAnalgesiaCancerGW PharmaceuticalsOncologyOptimized chronic opioid therapyPainPharmaceuticalRegulationSativexTreatment of pain in patients with advanced cancerUK

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

15-11-2013

GW Pharmaceuticals (Nasdaq: GWPH) has been granted orphan drug designation by the US Food and Drug Administration…

EuropeGW PharmaceuticalsNorth AmericaPharmaceuticalRare diseasesRegulationUKUSA

Back to top